Entera Bio Ltd. (ENTX) Stock

Entera Bio Ltd. (ENTX) is a Healthcare stock trading at $1.20 (as of 2026-06-18), with a market capitalization of $66.45M and a trailing P/E of 4.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing orally delivered large-molecule therapeutics. Its lead candidates include EB612 in Phase II for hypoparathyroidism and EB613, which has completed Phase II for osteoporosis and is in Phase I for non-union fractures, with a research collaboration and license agreement with Amgen for inflammatory disease and other serious illnesses.

Valuation — source: SEC EDGAR (first-party)
Price	$1.20
Market Cap	$66.45M
P/E Ratio	4.7
EV / EBITDA	-3.8
Price / Book	5.57
DCF Value (model)	$-2.41
DCF Upside vs Price	-301.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$42000.00
Net Margin	-27235.7%
Return on Equity	-115.8%
Current Ratio	7.93
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	16.7%
FCF Growth (YoY)	118.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.81 (distress)

Valuation vs Sector & Industry
Stock P/E	4.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-77.7%
vs Industry	-72.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Knoll Capital Management, LLC ($6.47M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Miranda J. Toledano
Employees	18
Country	IL
IPO Date	2018-06-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.